Interference of OX40-OX40L signaling presents as an attractive avenue of potential prophylaxis and/or therapy for a variety of fibrotic diseases including systemic sclerosis, pulmonary arterial hypertension, dermal fibrosis, and atherosclerosis. This evidence concerns the gene TNFRSF4 and systemic sclerosis.